Spiclomazine displays a preferential anti-tumor activity in mutant KRas-driven pancreatic cancer

Title
Spiclomazine displays a preferential anti-tumor activity in mutant KRas-driven pancreatic cancer
Authors
Keywords
pancreatic cancer; Ras; spiclomazine; targeted therapy; xenograft model
Journal
Oncotarget
Volume 9, Issue 6, Pages -
Publisher
Impact Journals, LLC
Online
2018-01-08
DOI
10.18632/oncotarget.24025

Ask authors/readers for more resources

Reprint

Contact the author

Find Funding. Review Successful Grants.

Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.

Explore

Find the ideal target journal for your manuscript

Explore over 38,000 international journals covering a vast array of academic fields.

Search